Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to four new employees. The grants were made under the company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Three employees received a total of 131,300 options at an exercise price of $8.46 per share, while one employee received 150,000 options at $8.87 per share. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly over the following three years, subject to continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), una compagnia biofarmaceutica in fase clinica, ha annunciato l'assegnazione di opzioni azionarie non statutarie a quattro nuovi dipendenti. Le assegnazioni sono state fatte nell'ambito del Piano di Incentivazione Azionaria per Induzione del 2022, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Tre dipendenti hanno ricevuto un totale di 131.300 opzioni a un prezzo di esercizio di 8,46 dollari per azione, mentre un dipendente ha ricevuto 150.000 opzioni a 8,87 dollari per azione. Queste opzioni hanno un termine di dieci anni e maturano in quattro anni, con il 25% che matura il primo anniversario e il restante 75% che matura trimestralmente nei tre anni successivi, a condizione di un impiego continuato.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica, ha anunciado la concesión de opciones sobre acciones no estatutarias a cuatro nuevos empleados. Las concesiones se realizaron bajo el Plan de Incentivo de Acciones por Inducción 2022 de la compañía, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq. Tres empleados recibieron un total de 131,300 opciones a un precio de ejercicio de $8.46 por acción, mientras que un empleado recibió 150,000 opciones a $8.87 por acción. Estas opciones tienen un plazo de diez años y se consolidan en cuatro años, con el 25% consolidándose en el primer aniversario y el 75% restante consolidándose trimestralmente durante los tres años siguientes, sujeto a la continuidad del empleo.
Fulcrum Therapeutics (Nasdaq: FULC), 임상 단계의 생명공학 회사는 4명의 신규 직원에게 비법정 주식 매수 선택권을 부여했다고 발표했습니다. 이 부여는 회사의 2022 유도 주식 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. 세 명의 직원이 총 131,300개의 옵션을 주당 8.46달러의 행사 가격으로 받았고, 한 명의 직원은 150,000개의 옵션을 주당 8.87달러로 받았습니다. 이 옵션은 10년의 만기와 4년에 걸쳐 분할된 권리 행사 조건을 가지고 있으며, 첫 해 기념일에 25%가 만기되고 나머지 75%는 이후 3년에 걸쳐 분기별로 만기됩니다. 단, 고용이 계속 유지되어야 합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique, a annoncé l'octroi d'options d'achat d'actions non statutaires à quatre nouveaux employés. Les attributions ont été faites dans le cadre du Plan d'Incentive d'Actions par Induction 2022 de l'entreprise, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq. Trois employés ont reçu un total de 131 300 options à un prix d'exercice de 8,46 $ par action, tandis qu'un employé a reçu 150 000 options à 8,87 $ par action. Ces options ont un terme de dix ans et sont acquises sur quatre ans, avec 25 % acquises à la première anniversaire et les 75 % restants acquises trimestriellement au cours des trois années suivantes, sous réserve d'un emploi continu.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in klinischer Phase, hat die Gewährung von nicht-statutären Aktienoptionen an vier neue Mitarbeiter bekannt gegeben. Die Gewährungen erfolgten im Rahmen des Aktienoptionsprogramms 2022, in Übereinstimmung mit der Nasdaq-Listungsregel 5635(c)(4). Drei Mitarbeiter erhielten insgesamt 131.300 Optionen zu einem Ausübungspreis von 8,46 $ pro Aktie, während ein Mitarbeiter 150.000 Optionen zu 8,87 $ pro Aktie erhielt. Diese Optionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre fällig, wobei 25 % am ersten Jahrestag fällig werden und die verbleibenden 75 % vierteljährlich in den folgenden drei Jahren fällig werden, vorbehaltlich einer Fortsetzung des Arbeitsverhältnisses.
- Fulcrum is attracting new talent by offering stock options as part of compensation packages
- The company is aligning employee interests with shareholder interests through equity-based incentives
- Potential dilution of existing shareholders' ownership due to the issuance of new stock options
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to four new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted three new employees an aggregate of 131,300 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
How many stock options did Fulcrum Therapeutics (FULC) grant to new employees?
What is the vesting schedule for the stock options granted by Fulcrum Therapeutics (FULC)?
What was the exercise price for the stock options granted by Fulcrum Therapeutics (FULC) on August 5, 2024?
Under which plan did Fulcrum Therapeutics (FULC) grant these stock options?
